
    
      -  Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in
           expansion cohort )

        -  Treatment :

             -  Vactosertib* 100-300 mg bid for 5 days

             -  Liposomal Irinotecan (Onivyde) 70mg/m2 on D1

             -  LV 200mg/m2 IV bolus on D1

             -  5-FU 2400mg/m2 CIV over 46 hours on D1

                  -  Vactosertib will be kindly provided by MedPacto.

        -  Disease evaluation: Tumor assessment will be conducted at screening and before Day 1 of
           every third cycle starting with Cycle 4

        -  Period : Approximately 24 months from the date of Institutional Review Board (IRB)
           approval

        -  Primary endpoint : To determine recommended phase 2 dose and to evaluate the safety of
           vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal
           adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel

        -  Secondary endpoint :

             -  Progression-Free Survival (PFS) (RECIST 1.1 criteria)

             -  Overall Survival (OS)

             -  Objective Response Rate (ORR) (RECIST 1.1 criteria)

             -  Disease Control Rate (DCR) (RECIST 1.1 criteria)

        -  Exploratory endpoint

             -  Pharmacokinetic assessment: before treatment, post treatment 1.5h, 4.5h, and
                8hPharmacodynamic assessment: to evaluate changes in the amount of p-SMAD in PBMC.

             -  Biomarker analysis in pre-treated and post-treated tumor samples
    
  